©2024 Stanford Medicine
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
Not Recruiting
Trial ID: NCT03558386
Purpose
This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as
assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64
years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic
syndromes (MDS).
Official Title
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
Stanford Investigator(s)
Lori Muffly
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:
In order to be eligible to participate on this study, an individual must meet all of the
following criteria:
1. Underwent an allogeneic HCT for MDS on the 10-CMSMDS-1 protocol
2. Prior consent to research and future contact by the CIBMTR
3. Ability to provide RCI BMT protocol 17-ePRO signed and dated informed consent form
(ICF)
4. Age ≥55 years at time of transplant
5. Fluent in English or Spanish
6. Greater than 6 months post-HCT
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation
on this study.
1. No access to an internet browser or email account
2. Within 6 months of first HCT for MDS on the 10-CMSMDS-1 protocol
Intervention(s):
behavioral: ePRO survey
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michelle Chin, MS
650-721-4183